株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

生体吸収性ステント:医療機器のパイプライン評価

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 347100
出版日 ページ情報 英文 118 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
生体吸収性ステント:医療機器のパイプライン評価 Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2017
出版日: 2017年09月08日 ページ情報: 英文 118 Pages
概要

当レポートでは、生体吸収性ステントのパイプライン製品について調査分析し、開発段階別の比較分析に焦点を当てて、パイプライン製品の開発に従事している主要企業、進行中の臨床試験に関する情報なども含めて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 生体吸収性ステントの概要

第3章 開発中の製品

  • 生体吸収性ステント - パイプライン製品:開発段階別
  • 生体吸収性ステント - パイプライン製品:地域別
  • 生体吸収性ステント - パイプライン製品:規制別
  • 生体吸収性ステント - パイプライン製品:承認予定日別
  • 生体吸収性ステント - 進行中の臨床試験

第4章 生体吸収性ステント - 開発中のパイプライン製品:企業別

  • 生体吸収性ステント企業 - パイプライン製品:開発段階別
  • 生体吸収性ステント - パイプライン製品:開発段階別

第5章 生体吸収性ステント企業と製品の概要

  • Abbott Vascular Inc.
  • AlviMedica Medical Technologies Inc.
  • Amaranth Medical, Inc.
  • Arterius Ltd
  • Biosensors International Group, Ltd.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • HangZhou HuaAn Biotechnology Co., Ltd.
  • Icon Interventional Systems, Inc.
  • 日本ステントテクノロジー
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Medlogics Device Corporation
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • NanoCoeur, Inc.
  • Northwestern University
  • OrbusNeich
  • REVA Medical, Inc.
  • S3V Vascular Technologies
  • Shanghai MicroPort Medical (Group) Co., Ltd.
  • Tepha, Inc.
  • Terumo Corporation
  • Xenogenics Corporation
  • Zorion Medical

第6章 生体吸収性ステント - 最近の動向

第7章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0443EPD

GlobalData's Medical Devices sector report, "Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2017" provides an overview of Bioabsorbable Stents (BAS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents (BAS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Bioabsorbable Stents (BAS) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 8

2 Introduction 9

  • 2.1 Bioabsorbable Stents (BAS) Overview 9

3 Products under Development 10

  • 3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 10
  • 3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory 11
  • 3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 12
  • 3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 13
  • 3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 14

4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies 15

  • 4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 15
  • 4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 16

5 Bioabsorbable Stents (BAS) Companies and Product Overview 17

  • 5.1 Abbott Vascular Inc Company Overview 17
    • 5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.2 Amaranth Medical Inc Company Overview 34
    • 5.2.1 Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.3 Arterius Ltd Company Overview 42
    • 5.3.1 Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.4 Bio DG Company Overview 43
    • 5.4.1 Bio DG Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.5 Biosten, LLC Company Overview 44
    • 5.5.1 Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.6 Biotronik SE & Co KG Company Overview 45
    • 5.6.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.7 Boston Scientific Corp Company Overview 48
    • 5.7.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.8 Cardionovum GmbH Company Overview 52
    • 5.8.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.9 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview 55
    • 5.9.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.10 Icon Interventional Systems, Inc. Company Overview 56
    • 5.10.1 Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.11 Japan Stent Technology Co., Ltd. Company Overview 57
    • 5.11.1 Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.12 Kyoto Medical Planning Co., Ltd. Company Overview 58
    • 5.12.1 Kyoto Medical Planning Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.13 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 59
    • 5.13.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.14 Medlogics Device Corp (Inactive) Company Overview 60
    • 5.14.1 Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.15 Michigan Technological University Company Overview 61
    • 5.15.1 Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.16 MicroPort Scientific Corp Company Overview 62
    • 5.16.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.17 NanoCoeur, Inc. Company Overview 63
    • 5.17.1 NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.18 North Carolina State University Company Overview 64
    • 5.18.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.19 Northwestern University Company Overview 65
    • 5.19.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.20 OrbusNeich Company Overview 66
    • 5.20.1 OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.21 REVA Medical Inc Company Overview 67
    • 5.21.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.22 S3V Vascular Technologies Company Overview 71
    • 5.22.1 S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview 71
  • 5.23 Shanghai MicroPort Medical Group Co Ltd Company Overview 72
    • 5.23.1 Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.24 Tepha Inc Company Overview 73
    • 5.24.1 Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.25 Xenogenics Corporation Company Overview 74
    • 5.25.1 Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 74

6 Bioabsorbable Stents (BAS)- Recent Developments 77

  • 6.1 Aug 11, 2017: MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261% 77
  • 6.2 Aug 10, 2017: REVA Medical: Half-Yearly Report 77
  • 6.3 Aug 04, 2017: Boston Scientific's Distribution Option Lapses 78
  • 6.4 Jul 31, 2017: REVA Medical: Quarter Ended 30 June 2017 79
  • 6.5 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 80
  • 6.6 Jul 24, 2017: MicroPort Attends EUROPACE-CARDIOSTIM 2017 81
  • 6.7 Jul 13, 2017: REVA Medical Announces Organizational Changes 82
  • 6.8 Jul 07, 2017: MPSC New COO Glendy Wang on Board 83
  • 6.9 Jun 28, 2017: REVA Medical: First Commercial Customer 83
  • 6.10 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 83
  • 6.11 Jun 09, 2017: REVA Medical: Changes to Board of Directors 85
  • 6.12 May 23, 2017: MicroPort Listed as Enterprises Conforming to CSR Standards for Six Consecutive Years 86
  • 6.13 May 18, 2017: REVA Symposium Showcases Clinical Data 86
  • 6.14 May 16, 2017: REVA Announces Positive 12-Month Clinical Results 87
  • 6.15 May 16, 2017: Amaranth Medical Provides Clinical and Commercial Update on 115-micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold 87
  • 6.16 May 02, 2017: TGA Hazard Alert On Absorb Bioresorbable Vascular Scaffold System 88
  • 6.17 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 89
  • 6.18 Apr 26, 2017: Enrollment Initiated in Expanded FANTOM II Trial 90
  • 6.19 Apr 11, 2017: REVA to Present at EuroPCR 2017 90
  • 6.20 Apr 03, 2017: REVA Receives CE Mark for Fantom 91
  • 6.21 Mar 30, 2017: MPSC Announces 2016 Annual Results 91
  • 6.22 Mar 27, 2017: Abbott Vascular Provides Update On Absorb Bioresorbable Vascular Scaffold 93
  • 6.23 Mar 24, 2017: LifeTech Announces 2016 Annual Results 93
  • 6.24 Mar 23, 2017: REVA to Expand FANTOM II Trial to More Complex Cases 95
  • 6.25 Mar 18, 2017: Absorb GT1 Bioresorbable Vascular Scaffold by Abbott Vascular: Letter to Health Care Providers - FDA Investigating Increased Rate of Major Adverse Cardiac Events 96
  • 6.26 Feb 21, 2017: Ascension Michigan Leads State in Pioneering Dissolving Heart Stent 97
  • 6.27 Feb 17, 2017: Absorbable Stents Offer Alternative for Wake Forest Baptist Cardiology Patients 97
  • 6.28 Feb 09, 2017: Terumo Announces Change of Executive Officers 98
  • 6.29 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 99
  • 6.30 Jan 31, 2017: REVA Medical: Quarter Ended 31 December 2016 101
  • 6.31 Jan 31, 2017: Terumo Opens a Branch in Yangon 102
  • 6.32 Dec 28, 2016: MicroPort was selected as a pilot project of Patent Alliance of Enterprises in Shanghai Zhangjiang National Innovation Demonstration Zone 102
  • 6.33 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy 103
  • 6.34 Nov 07, 2016: Abbott's Absorb Bioresorbable Stent Approved as the First Fully Dissolving Heart Stent in Japan 103
  • 6.35 Nov 01, 2016: Amaranth Medical Initiates Trial of Sub-100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold 104
  • 6.36 Oct 31, 2016: REVA Releases Positive Data for Fantom at TCT 104
  • 6.37 Oct 31, 2016: Amaranth Medical 9-Months Clinical and Imaging Results of the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented at TCT 105
  • 6.38 Oct 31, 2016: TCT 2016 First report Investigations Examine Potential for Novel Bioresorbable Stent Technologies 106
  • 6.39 Oct 28, 2016: REVA Medical: Quarter Ended 30 September 2016 108
  • 6.40 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 108
  • 6.41 Oct 25, 2016: Aurora St. Luke's Medical Center is region's first hospital to implant new bioresorbable stent to treat coronary artery disease 110
  • 6.42 Oct 19, 2016: Elixir Medical Announces Schedule of Programs for TCT 2016 111
  • 6.43 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 113
  • 6.44 Sep 28, 2016: Nevada Heart And Vascular Center Announces Partnership With Desert Springs Hospital Offering First-Of-Its-Kind Naturally Dissolving Heart Stent For Patients With Coronary Artery Disease 114
  • 6.45 Sep 27, 2016: MicroPort Hosts First EMEA Regional Distributor Summit 114

7 Appendix 115

  • 7.1 Methodology 115
  • 7.2 About GlobalData 118
  • 7.3 Contact Us 118
  • 7.4 Disclaimer 118

List of Tables

1.1 List of Tables

  • Table 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 10
  • Table 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory 11
  • Table 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 12
  • Table 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 13
  • Table 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 14
  • Table 6: Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development 15
  • Table 7: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 16
  • Table 8: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 9: Absorb GT1 Bioresorbable Vascular Scaffold - Product Status 17
  • Table 10: Absorb GT1 Bioresorbable Vascular Scaffold - Product Description 18
  • Table 11: Second Generation Bioresorbable Vascular Scaffold - Product Status 18
  • Table 12: Second Generation Bioresorbable Vascular Scaffold - Product Description 18
  • Table 13: Abbott Vascular Inc - Ongoing Clinical Trials Overview 19
  • Table 14: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects with de Novo Native Coronary Artery Lesions in Chinese Population 22
  • Table 15: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions 22
  • Table 16: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold In the Treatment of Subjects with De Novo Native Coronary Artery Lesions 23
  • Table 17: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients with de Novo Native Coronary Artery Lesions 23
  • Table 18: Absorb GT1 Bioresorbable Vascular Scaffold - A Continuation in the Clinical Evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) System in the Treatment of Subjects with de Novo Native Coronary Artery Lesions: ABSORB EXTEND Clinical Investigation 24
  • Table 19: Absorb GT1 Bioresorbable Vascular Scaffold - A Multicenter Prospective Natural History Study Using Multimodality Imaging in Patients with Acute Coronary Syndromes - PROSPECT II (Natural History Study), Combined with a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial) 24
  • Table 20: Absorb GT1 Bioresorbable Vascular Scaffold - A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Registry 25
  • Table 21: Absorb GT1 Bioresorbable Vascular Scaffold - A Prospective, Randomized Trial of Synergy Bioresorbable Polymer Coated Stents Versus Absorb Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB) 25
  • Table 22: Absorb GT1 Bioresorbable Vascular Scaffold - A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold versus Everolimus-eluting Metallic Stent in Long Coronary Lesions 25
  • Table 23: Absorb GT1 Bioresorbable Vascular Scaffold - A Randomized Trial of the Treatment of Non- Culprit Lesion After STEMI: Bioresorbable Vascular Scaffold Versus Optimal Medical Therapy (NCL Study) 26
  • Table 24: Absorb GT1 Bioresorbable Vascular Scaffold - ABSORB Bioresorbable Scaffold versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis 26
  • Table 25: Absorb GT1 Bioresorbable Vascular Scaffold - ABSORB Post-approval Clinical Study 26
  • Table 26: Absorb GT1 Bioresorbable Vascular Scaffold - Amsterdam Investigator-initiated Absorb Strategy All-comers Trial (AIDA Trial) - A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers 27
  • Table 27: Absorb GT1 Bioresorbable Vascular Scaffold - Bifurcation ABSORB OCT Trial 27
  • Table 28: Absorb GT1 Bioresorbable Vascular Scaffold - Bioresorbable Vascular Stents for Treatment of Coronary Bifurcation Lesions Assessed by Optical Coherence Tomography - The BIFSORB Study 27
  • Table 29: Absorb GT1 Bioresorbable Vascular Scaffold - Clinical Study on Absorb Polylactic, Reabsorbable Coronary Scaffold (RAI) 28
  • Table 30: Absorb GT1 Bioresorbable Vascular Scaffold - Comparison of the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold System with a Drug- Eluting Metal Stent (Xience) in Acute ST-Elevation Myocardial Infarction 28
  • Table 31: Absorb GT1 Bioresorbable Vascular Scaffold - Complex Bifurcation Lesions - A Randomized Comparison Between the AXXESS Device in Combination with Absorb BVS, and Modified T Stenting with Absorb BVS: An OCT Study 28
  • Table 32: Absorb GT1 Bioresorbable Vascular Scaffold - Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms - A Multi-modality, Multi-specialty Collaborative Study: PERFECT Program 29
  • Table 33: Absorb GT1 Bioresorbable Vascular Scaffold - Dissection Re-entry Evaluation with Absorb Bioresorbable Vascular Scaffolds in Chronic Total Occlusion - The Discrete CTO Study 29
  • Table 34: Absorb GT1 Bioresorbable Vascular Scaffold - Evaluation of Microcirculatory Protection in Percutaneous Revascularisation with Bioresorbable Vascular Scaffolds Versus Metallic Drug-eluting Stents: A Device- and Implant Technique-based Comparison 30
  • Table 35: Absorb GT1 Bioresorbable Vascular Scaffold - Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease 30
  • Table 36: Absorb GT1 Bioresorbable Vascular Scaffold - Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study 30
  • Table 37: Absorb GT1 Bioresorbable Vascular Scaffold - German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System in Patients with Coronary Artery Stenosis 31
  • Table 38: Absorb GT1 Bioresorbable Vascular Scaffold - Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: A Randomized H215O PET/CT Study 31
  • Table 39: Absorb GT1 Bioresorbable Vascular Scaffold - Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography: Insights From the International INVEST Registry 31
  • Table 40: Absorb GT1 Bioresorbable Vascular Scaffold - Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis 32
  • Table 41: Absorb GT1 Bioresorbable Vascular Scaffold - Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI) 32
  • Table 42: Absorb GT1 Bioresorbable Vascular Scaffold - Prospective Study of Bioresorbable Vascular Scaffold Treatment with Scoring Balloon Pre-dilatation in Patients with In-stent Restenosis 32
  • Table 43: Absorb GT1 Bioresorbable Vascular Scaffold - Real World Advanced Experience of Bioresorbable Scaffold by Smart Angioplasty Research Team (SMART REWARD) 33
  • Table 44: Absorb GT1 Bioresorbable Vascular Scaffold - Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients with Internal Pudendal Artery-related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB) 33
  • Table 45: Absorb GT1 Bioresorbable Vascular Scaffold - Strut Coverage with SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction: An Intracoronary Optical Coherence Tomography Randomized Study 33
  • Table 46: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 47: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status 34
  • Table 48: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description 34
  • Table 49: FORTITUDE Scaffold - Product Status 35
  • Table 50: FORTITUDE Scaffold - Product Description 35
  • Table 51: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status 35
  • Table 52: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description 36
  • Table 53: Next Generation FORTITUDE Scaffold - Product Status 36
  • Table 54: Next Generation FORTITUDE Scaffold - Product Description 36
  • Table 55: Amaranth Medical Inc - Ongoing Clinical Trials Overview 37
  • Table 56: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial 38
  • Table 57: Next Generation FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold 39
  • Table 58: APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II 40
  • Table 59: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Clinical Study of Fourth-generation MAGNITUDE Scaffold 41
  • Table 60: MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III 41
  • Table 61: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 62: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status 42
  • Table 63: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description 42
  • Table 64: Bio DG Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 65: Biodegradable Stent - Product Status 43
  • Table 66: Biodegradable Stent - Product Description 43
  • Table 67: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 68: Biodegradable Endovascular Implant - Product Status 44
  • Table 69: Biodegradable Endovascular Implant - Product Description 44
  • Table 70: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 71: AMS-1 - Product Status 45
  • Table 72: AMS-1 - Product Description 45
  • Table 73: AMS-2 - Product Status 46
  • Table 74: AMS-2 - Product Description 46
  • Table 75: DREAMS - Product Status 46
  • Table 76: DREAMS - Product Description 47
  • Table 77: DREAMS 2G - Product Status 47
  • Table 78: DREAMS 2G - Product Description 47
  • Table 79: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 80: Fully Resorbable Drug-Eluting Scaffold System - Product Status 48
  • Table 81: Fully Resorbable Drug-Eluting Scaffold System - Product Description 49
  • Table 82: Next Generation SYNERGY - Product Status 49
  • Table 83: Next Generation SYNERGY - Product Description 49
  • Table 84: Boston Scientific Corp - Ongoing Clinical Trials Overview 50
  • Table 85: Fully Resorbable Drug-Eluting Scaffold System - Fully Absorbable Scaffold Feasibility Study 51
  • Table 86: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 87: ReNATURAL (M) - Product Status 52
  • Table 88: ReNATURAL (M) - Product Description 52
  • Table 89: ReNATURAL (P) - Product Status 53
  • Table 90: ReNATURAL (P) - Product Description 53
  • Table 91: RESORB - Product Status 53
  • Table 92: RESORB - Product Description 54
  • Table 93: HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 94: Xinsorb BRS - Product Status 55
  • Table 95: Xinsorb BRS - Product Description 55
  • Table 96: Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 97: Biosorb Pediatric Dissolving Stent - Product Status 56
  • Table 98: Biosorb Pediatric Dissolving Stent - Product Description 56
  • Table 99: Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 100: Bioabsorbable Stent - Product Status 57
  • Table 101: Bioabsorbable Stent - Product Description 57
  • Table 102: Kyoto Medical Planning Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 103: Igaki-Tamai Coronary Stent - Product Status 58
  • Table 104: Igaki-Tamai Coronary Stent - Product Description 58
  • Table 105: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 106: Absorbable Coronary Stent - Product Status 59
  • Table 107: Absorbable Coronary Stent - Product Description 59
  • Table 108: Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 109: COBRA-P Drug Eluting Stent - Product Status 60
  • Table 110: COBRA-P Drug Eluting Stent - Product Description 60
  • Table 111: Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 112: Bioabsorbable Stent - Product Status 61
  • Table 113: Bioabsorbable Stent - Product Description 61
  • Table 114: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 115: Firefalcon Bioresorbable Device - Product Status 62
  • Table 116: Firefalcon Bioresorbable Device - Product Description 62
  • Table 117: NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 118: Nanocoating Cardiac Stent - Product Status 63
  • Table 119: Nanocoating Cardiac Stent - Product Description 63
  • Table 120: North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 121: Biodegradable Metal Stent - Product Status 64
  • Table 122: Biodegradable Metal Stent - Product Description 64
  • Table 123: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 124: Liquid Biodegradable Drug Eluting Stent - Product Status 65
  • Table 125: Liquid Biodegradable Drug Eluting Stent - Product Description 65
  • Table 126: OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 127: ON-AVS Scaffold - Product Status 66
  • Table 128: ON-AVS Scaffold - Product Description 66
  • Table 129: REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 130: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status 67
  • Table 131: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description 67
  • Table 132: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Thinner Version - Product Status 68
  • Table 133: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Thinner Version - Product Description 68
  • Table 134: REVA Medical Inc - Ongoing Clinical Trials Overview 69
  • Table 135: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Expanded FANTOM II Clinical Study 70
  • Table 136: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold 70
  • Table 137: Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Safety & Performance Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold 70
  • Table 138: S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 139: 3V Avatar - Product Status 71
  • Table 140: 3V Avatar - Product Description 71
  • Table 141: Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 142: Bioresorbable Scaffold System - Product Status 72
  • Table 143: Bioresorbable Scaffold System - Product Description 72
  • Table 144: Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 145: TephaFLEX Absorbable Coronary Stent - Product Status 73
  • Table 146: TephaFLEX Absorbable Coronary Stent - Product Description 73
  • Table 147: Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 148: Ideal BioStent - First Generation - Product Status 74
  • Table 149: Ideal BioStent - First Generation - Product Description 74
  • Table 150: Ideal BioStent - Second Generation - Product Status 75
  • Table 151: Ideal BioStent - Second Generation - Product Description 75
  • Table 152: IDEAL Stent - Product Status 75
  • Table 153: IDEAL Stent - Product Description 76
  • Table 154: Whisper Coronary Stent System - Product Status 76
  • Table 155: Whisper Coronary Stent System - Product Description 76
  • Table 156: Glossary 117

List of Figures

1.2 List of Figures

  • Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development 10
  • Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory 11
  • Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path 12
  • Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date 13
  • Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials 14
Back to Top